In addition to its recognized oncogenic role, mutant KRAS seems to drive the formation of immunosuppressed TIME, directly preventing innate and adaptative anti-tumor immunity by modulating the levels of cell surface HLA class I and by regulating the expression of CD47 and PD-L1 [75,76,77]. Here, CD274 is linked to neoplasm.